Ignite Creation Date:
2025-12-24 @ 11:08 PM
Ignite Modification Date:
2026-01-04 @ 2:53 AM
Study NCT ID:
NCT04164069
Status:
COMPLETED
Last Update Posted:
2024-12-27
First Post:
2019-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Sponsor:
Anne Noonan
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Colorectal Carcinoma | View |
| None | Metastatic Colorectal Carcinoma | View |
| None | Stage IV Colorectal Cancer AJCC v8 | View |
| None | Stage IVA Colorectal Cancer AJCC v8 | View |
| None | Stage IVB Colorectal Cancer AJCC v8 | View |
| None | Stage IVC Colorectal Cancer AJCC v8 | View |
| None | Stage II Colon Cancer | View |
| None | Stage II Rectal Cancer | View |
| None | Stage III Colon Cancer | View |
| None | Stage III Rectal Cancer | View |
| None | Esophageal Cancer | View |
| None | Pancreatic Cancer | View |
| None | Bile Duct Cancer | View |
| None | Gastric Cancer | View |
| None | Gall Bladder Cancer | View |
| None | Small Bowel Adenocarcinoma | View |
Keywords: